Platelets and von Willebrand factor in atherogenesis.

The role of platelet adhesion, activation, and aggregation in acute atherothrombotic events such as myocardial infarction and stroke is well established. There is increasing evidence that platelet-endothelial interactions also contribute to early atherosclerotic plaque initiation and growth. Through these interactions, platelet-derived factors can contribute to the proinflammatory and mitogenic status of resident mural cells. Among the many putative mechanisms for platelet-endothelial interactions, increased endothelial-associated von Willebrand factor, particularly in a multimerized form, which interacts with platelet glycoproteins and integrins, is a major factor and represents a therapeutic target in early atherogenesis.

[1]  B. Kaufmann,et al.  Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling , 2016, The Journal of Immunology.

[2]  O. Franco,et al.  Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[3]  L. Uhlmann,et al.  Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis , 2016, Drug design, development and therapy.

[4]  P. Libby,et al.  Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials , 2016, Thrombosis and Haemostasis.

[5]  O. Franco,et al.  Low ADAMTS‐13 activity and the risk of coronary heart disease – a prospective cohort study: the Rotterdam Study , 2016, Journal of thrombosis and haemostasis : JTH.

[6]  M. Schattner,et al.  Platelets: New Bricks in the Building of Neutrophil Extracellular Traps , 2016, Front. Immunol..

[7]  C. Ballantyne,et al.  Defective Association of the Platelet Glycoprotein Ib–IX Complex with the Glycosphingolipid-Enriched Membrane Domain Inhibits Murine Thrombus and Atheroma Formation , 2016, The Journal of Immunology.

[8]  F. Peyvandi,et al.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. , 2016, The New England journal of medicine.

[9]  Yan-Wei Hu,et al.  Possible roles of platelet-derived microparticles in atherosclerosis. , 2016, Atherosclerosis.

[10]  Junmei Chen,et al.  High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. , 2016, Blood.

[11]  L. Badimón,et al.  High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis , 2015, Thrombosis and Haemostasis.

[12]  P. Metharom,et al.  Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbα , 2015, Redox biology.

[13]  H. Jo,et al.  Flow-dependent expression of ectonucleotide tri(di)phosphohydrolase-1 and suppression of atherosclerosis. , 2015, The Journal of clinical investigation.

[14]  Ying Zheng,et al.  Flow-driven assembly of VWF fibres and webs in in vitro microvessels , 2015, Nature Communications.

[15]  J. Lindner,et al.  Molecular Imaging of Platelet–Endothelial Interactions and Endothelial von Willebrand Factor in Early and Mid-Stage Atherosclerosis , 2015, Circulation. Cardiovascular imaging.

[16]  C. Bruehl,et al.  Mechanism and functional impact of CD40 ligand-induced von Willebrand factor release from endothelial cells , 2015, Thrombosis and Haemostasis.

[17]  Junmei Chen,et al.  Hypochlorous Acid Generated by Neutrophils Inactivates ADAMTS13 , 2014, The Journal of Biological Chemistry.

[18]  J. Deckers,et al.  'Corrigendum to "Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients" [Atherosclerosis 207 (2009) 250-4]' , 2014 .

[19]  P. von Hundelshausen,et al.  Platelets and their chemokines in atherosclerosis—clinical applications , 2014, Front. Physiol..

[20]  K. Ley,et al.  Genetic deletion of platelet glycoprotein Ib alpha but not its extracellular domain protects from atherosclerosis , 2014, Thrombosis and Haemostasis.

[21]  S. Israels,et al.  Markers of Platelet Activation Are Increased in Adolescents With Type 2 Diabetes , 2014, Diabetes Care.

[22]  A. Chauhan,et al.  ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF‐dependent mechanism , 2014, Journal of thrombosis and haemostasis : JTH.

[23]  J. Cho Protein disulfide isomerase in thrombosis and vascular inflammation , 2013, Journal of thrombosis and haemostasis : JTH.

[24]  A. Weyrich,et al.  Platelets as cellular effectors of inflammation in vascular diseases. , 2013, Circulation research.

[25]  S. D. De Meyer,et al.  Unwinding the von Willebrand factor strings puzzle. , 2013, Blood.

[26]  O. McCarty,et al.  Molecular Imaging of Inflammation and Platelet Adhesion in Advanced Atherosclerosis Effects of Antioxidant Therapy With NADPH Oxidase Inhibition , 2013, Circulation. Cardiovascular imaging.

[27]  D. Rader,et al.  Genetic Ablation of Adamts13 Gene Dramatically Accelerates the Formation of Early Atherosclerosis in a Murine Model , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[28]  D. Bonatto,et al.  Protein Disulfide Isomerase Is Required for Platelet-derived Growth Factor-induced Vascular Smooth Muscle Cell Migration, Nox1 NADPH Oxidase Expression, and RhoGTPase Activation , 2012, The Journal of Biological Chemistry.

[29]  S. Basili,et al.  Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2 , 2012, Circulation.

[30]  A. Chauhan,et al.  ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. , 2012, Blood.

[31]  P. Gresele,et al.  Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V. , 2012, Handbook of experimental pharmacology.

[32]  J. Italiano,et al.  Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. , 2011, Blood.

[33]  H. Deckmyn,et al.  The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib. , 2011, Blood.

[34]  K. Ravid,et al.  Adenosine and blood platelets , 2011, Purinergic Signalling.

[35]  D. Scholtens,et al.  The Hemostatic System as a Modulator of Atherosclerosis , 2011 .

[36]  P. Mannucci Platelet/von Willebrand factor inhibitors to the rescue of ischemic stroke. , 2010, Arteriosclerosis, Thrombosis and Vascular Biology.

[37]  O. McCarty,et al.  Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype. , 2010, JACC. Cardiovascular imaging.

[38]  Junmei Chen,et al.  Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. , 2010, Blood.

[39]  C. Gachet,et al.  Studies of mice lacking the GPIb‐V‐IX complex question the role of this receptor in atherosclerosis , 2009, Journal of thrombosis and haemostasis : JTH.

[40]  P. Hordijk,et al.  Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases , 2009, Journal of leukocyte biology.

[41]  C. Gleissner,et al.  Platelet Chemokines in Vascular Disease , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[42]  Jizhong Lou,et al.  Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. , 2008, The Journal of clinical investigation.

[43]  P. Hordijk,et al.  Transendothelial migration drives dissociation of plateletmonocyte complexes , 2008, Thrombosis and Haemostasis.

[44]  X. Zheng,et al.  Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells , 2008, Journal of thrombosis and haemostasis : JTH.

[45]  B. Jilma,et al.  Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes , 2008, Circulation.

[46]  M. Gawaz,et al.  Platelet-vessel Wall Interactions in Atherosclerotic Disease Theme Issue Article Platelet Secretion Andgeneration of Cytokines , 2022 .

[47]  N. Caplice,et al.  Plaque neovascularization and antiangiogenic therapy for atherosclerosis. , 2007, Journal of the American College of Cardiology.

[48]  A. Chauhan,et al.  Formation of platelet strings and microthrombi in the presence of ADAMTS‐13 inhibitor does not require P‐selectin or β3 integrin , 2007, Journal of thrombosis and haemostasis : JTH.

[49]  W. Siess,et al.  Glycoprotein Ibα inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques , 2007, Thrombosis and Haemostasis.

[50]  Z. Ruggeri,et al.  The role of von Willebrand factor in thrombus formation. , 2007, Thrombosis research.

[51]  J. Akkerman,et al.  Platelet Activation by Low Density Lipoprotein and High Density Lipoprotein , 2006, Pathophysiology of Haemostasis and Thrombosis.

[52]  T. Ohmori,et al.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. , 2006, Blood.

[53]  M. Gawaz,et al.  Platelets in inflammation and atherogenesis. , 2005, The Journal of clinical investigation.

[54]  J. Loscalzo,et al.  Endogenous Mechanisms of Inhibition of Platelet Function , 2005, Microcirculation.

[55]  O. McCarty,et al.  Preferential binding of platelets to monocytes over neutrophils under flow. , 2005, Biochemical and biophysical research communications.

[56]  C. Weber Platelets and chemokines in atherosclerosis: partners in crime. , 2005, Circulation research.

[57]  D. Lane,et al.  Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. , 2005, Blood.

[58]  B. Jilma,et al.  Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation , 2005, Thrombosis and Haemostasis.

[59]  P. Ganz,et al.  Role of Endothelial Dysfunction in Atherosclerosis , 2004, Circulation.

[60]  S. Nagueh,et al.  Avoiding Papillary Muscle Infarction With Myocardial Contrast Echocardiographic Guidance of Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy , 2004 .

[61]  K. Ley,et al.  Role of platelets in the development of atherosclerosis. , 2004, Trends in cardiovascular medicine.

[62]  Z. Ruggeri,et al.  Von Willebrand factor, platelets and endothelial cell interactions , 2003, Journal of thrombosis and haemostasis : JTH.

[63]  Andreas Schober,et al.  Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E , 2003, Nature Medicine.

[64]  Andrew S. Holmes,et al.  Platelets and Cardiovascular Disease , 2002, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[65]  Kazuo Fujikawa,et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. , 2002, Blood.

[66]  Zaverio M. Ruggeri,et al.  Platelets in atherothrombosis , 2002, Nature Medicine.

[67]  M. Gawaz,et al.  A Critical Role of Platelet Adhesion in the Initiation of Atherosclerotic Lesion Formation , 2002, The Journal of experimental medicine.

[68]  K. Ley,et al.  Deposition of Platelet RANTES Triggering Monocyte Recruitment Requires P-Selectin and Is Involved in Neointima Formation After Arterial Injury , 2002, Circulation.

[69]  A. Zeiher,et al.  CD40 Ligand Inhibits Endothelial Cell Migration by Increasing Production of Endothelial Reactive Oxygen Species , 2002, Circulation.

[70]  Volker Klauss,et al.  NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. , 2002, Blood.

[71]  J. Vermylen,et al.  atherosclerosis-prone sites in response to hypercholesterolemia Endothelial von Willebrand factor recruits platelets to , 2013 .

[72]  K. Hirata,et al.  Involvement of NADH/NADPH oxidase in human platelet ROS production. , 2001, Thrombosis research.

[73]  C. Esmon,et al.  Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. , 2001, The American journal of pathology.

[74]  D. Wagner,et al.  Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. , 2001, Blood.

[75]  K. Ley,et al.  RANTES Deposition by Platelets Triggers Monocyte Arrest on Inflamed and Atherosclerotic Endothelium , 2001, Circulation.

[76]  Renu Virmani,et al.  Healed Plaque Ruptures and Sudden Coronary Death: Evidence That Subclinical Rupture Has a Role in Plaque Progression , 2001, Circulation.

[77]  R. Gryglewski,et al.  Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation. , 2001, Medical science monitor : international medical journal of experimental and clinical research.

[78]  R. Hynes,et al.  Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. , 2000, Blood.

[79]  R. Kroczek,et al.  Activated Platelets Induce Tissue Factor Expression on Human Umbilical Vein Endothelial Cells by Ligation of CD40 , 1998, Thrombosis and Haemostasis.

[80]  L. Koenderman,et al.  P‐selectin and MAC‐1 mediate monocyte rolling and adhesion to ECM‐bound platelets under flow conditions , 1998, Journal of leukocyte biology.

[81]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[82]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[83]  W. Haefeli,et al.  Acute von Willebrand Factor Secretion from the Endothelium In Vivo: Assessment through Plasma Propeptide (vWf:AgII) Levels , 1997, Thrombosis and Haemostasis.

[84]  C. Wollheim,et al.  Reactive oxygen intermediates induce regulated secretion of von Willebrand factor from cultured human vascular endothelial cells. , 1995, Blood.

[85]  A. Hamsten,et al.  Increased platelet-derived mitogenic activity in plasma of young patients with coronary atherosclerosis. , 1986, Atherosclerosis.